bioAffinity Technologies, Inc. (NASDAQ:BIAF) Shares Shorted: Short Interest Up 61.9% in September

Posted by Francis Steltz on Sep 30th, 2026

bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totaling 71,167 shares, a growth of 61.9% from the August 31st total of 43,959 shares. Approximately 12.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 14,456,534 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

A number of research analysts recently commented on BIAF shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. Wall Street Zen upgraded bioAffinity Technologies from a “sell” rating to a “hold” rating in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on BIAF

bioAffinity Technologies Trading Down 2.6%

Shares of BIAF stock traded down $0.18 during trading hours on Wednesday, reaching $6.70. 74,947 shares of the stock were exchanged, compared to its average volume of 1,264,941. bioAffinity Technologies has a 12-month low of $4.56 and a 12-month high of $80.70. The company has a current ratio of 1.44, a quick ratio of 1.41 and a debt-to-equity ratio of 0.14. The company’s 50-day moving average price is $8.05 and its 200-day moving average price is $22.35. The firm has a market capitalization of $4.03 million, a price-to-earnings ratio of -0.06 and a beta of -1.11.

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($31.50) by $30.86. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 220.52%. The company had revenue of $1.51 million for the quarter, compared to analyst estimates of $1.70 million.

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently bought a new position in bioAffinity Technologies stock. J. Safra Sarasin Holding AG acquired a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 42,600 shares of the company’s stock, valued at approximately $164,000. J. Safra Sarasin Holding AG owned 0.95% of bioAffinity Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

(Get Free Report)

bioAffinity Technologies, Inc is a biotechnology company focused on developing diagnostics and therapeutics for cancer and other serious diseases. The company’s technology uses porphyrin compounds that can selectively interact with cancer cells, supporting applications in both disease detection and treatment.

Its lead diagnostic product, CyPath Lung, is a noninvasive urine-based test designed to aid in the early detection of lung cancer. The test is intended to identify cancer-related signals in urine and is being developed as an alternative or complement to existing screening and diagnostic methods.

bioAffinity is also developing porphyrin-based therapeutic programs, including inhaled treatments intended to target cancer cells in the lungs.